secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001628280-23-009345
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience reports FY2022 revenue $15.2M; PRECISION-1 data Q2 2023
-----------------------------------------------------------------------

- FY 2022 total revenue $15.2M from FYARRO (10 months); Q4 net product sales $5.2M (+23% QoQ).
- Net loss $60.5M for FY2022 vs $110.1M in FY2021 (prior year incl $74.2M impairment).
- Cash $172.6M at Dec 31, 2022; cash runway into 2025 after $72.5M Q4 financing.
- PRECISION-1 trial preliminary data on TSC1/TSC2 alterations expected Q2 2023.
- Appointed Dr. Mohammad Hirmand to Board; collaboration with Mirati on adagrasib combo trial start Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/aadi-20230324.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-009345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer